FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226127130> ?p ?o ?g. }

• W4226127130 endingPage "998" @default.
• W4226127130 startingPage "985" @default.
• W4226127130 abstract "Stereotactic radiosurgery (SRS) has been increasingly employed in recent years to treat intracranial metastatic lesions. However, there is still a need for optimization of treatment paradigms to provide better local control and prevent progressive intracranial disease. In the current study, the authors utilized a national collaborative registry to investigate the outcomes of patients with intracranial metastatic disease who underwent SRS and to determine factors associated with lesion treatment response, overall progression, and mortality.The NeuroPoint Alliance SRS registry was queried for all patients with intracranial metastatic lesions undergoing single- or multifraction SRS at participating institutions between 2016 and 2020. The main outcomes of interest included lesion response (lesion-level analysis), progression using Response Assessment for Neuro-Oncology criteria, and mortality (patient-level analysis). Kaplan-Meier analysis was used to report time to progression and overall survival, and multivariable Cox proportional hazards analysis was used to investigate factors associated with lesion response, progression, and mortality.A total of 501 patients (1447 intracranial metastatic lesions) who underwent SRS and had available follow-up were included in the current analyses. The most common primary tumor was lung cancer (49.5%, n = 248), followed by breast (15.4%, n = 77) and melanoma (12.2%, n = 61). Most patients had a single lesion (44.9%, n = 225), 29.3% (n = 147) had 2 or 3 lesions, and 25.7% (n = 129) had > 3 lesions. The mean sum of baseline measurements of the lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) was 35.54 mm (SD 25.94). At follow-up, 671 lesions (46.4%) had a complete response, 631 (43.6%) had a partial response (≥ 30% decrease in longest diameter) or were stable (< 30% decrease but < 20% increase), and 145 (10%) showed progression (> 20% increase in longest diameter). On multivariable Cox proportional hazards analysis, melanoma-associated lesions (HR 0.48, 95% CI 0.34-0.67; p < 0.001) and larger lesion size (HR 0.94, 95% CI 0.93-0.96; p < 0.001) showed lower odds of lesion regression, while a higher biologically effective dose was associated with higher odds (HR 1.001, 95% CI 1.0001-1.00023; p < 0.001). A total of 237 patients (47.3%) had overall progression (local failure or intracranial progressive disease), with a median time to progression of 10.03 months after the index SRS. Factors found to be associated with increased hazards of progression included male sex (HR 1.48, 95% CI 1.108-1.99; p = 0.008), while administration of immunotherapy (before or after SRS) was found to be associated with lower hazards of overall progression (HR 0.62, 95% CI 0.460-0.85; p = 0.003). A total of 121 patients (23.95%) died during the follow-up period, with a median survival of 19.4 months from the time of initial SRS. A higher recursive partitioning analysis score (HR 21.3485, 95% CI 1.53202-3.6285; p < 0.001) was found to be associated with higher hazards of mortality, while single-fraction treatment compared with hypofractionated treatment (HR 0.082, 95% CI 0.011-0.61; p = 0.015), administration of immunotherapy (HR 0.385, 95% CI 0.233-0.64; p < 0.001), and presence of single compared with > 3 lesions (HR 0.427, 95% CI 0.187-0.98; p = 0.044) were found to be associated with lower risk of mortality.The comparability of results between this study and those of previously published clinical trials affirms the value of multicenter databases with real-world data collected without predetermined research purpose." @default.
• W4226127130 created "2022-05-05" @default.
• W4226127130 creator A5017468691 @default.
• W4226127130 creator A5030704684 @default.
• W4226127130 creator A5043879863 @default.
• W4226127130 creator A5052966036 @default.
• W4226127130 creator A5054814683 @default.
• W4226127130 creator A5056072781 @default.
• W4226127130 creator A5058373918 @default.
• W4226127130 creator A5059739662 @default.
• W4226127130 creator A5059890725 @default.
• W4226127130 creator A5060868189 @default.
• W4226127130 creator A5066158171 @default.
• W4226127130 creator A5068359755 @default.
• W4226127130 creator A5080962078 @default.
• W4226127130 creator A5084998801 @default.
• W4226127130 creator A5090675288 @default.
• W4226127130 date "2022-10-01" @default.
• W4226127130 modified "2023-10-16" @default.
• W4226127130 title "Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry" @default.
• W4226127130 cites W1532429101 @default.
• W4226127130 cites W1575301648 @default.
• W4226127130 cites W1836686668 @default.
• W4226127130 cites W2013843382 @default.
• W4226127130 cites W2030696130 @default.
• W4226127130 cites W2035280631 @default.
• W4226127130 cites W2047930883 @default.
• W4226127130 cites W2056697517 @default.
• W4226127130 cites W2074933858 @default.
• W4226127130 cites W2078143205 @default.
• W4226127130 cites W2083128109 @default.
• W4226127130 cites W2123894372 @default.
• W4226127130 cites W2143843774 @default.
• W4226127130 cites W2145376545 @default.
• W4226127130 cites W2302127234 @default.
• W4226127130 cites W2314595137 @default.
• W4226127130 cites W2550322313 @default.
• W4226127130 cites W2586643535 @default.
• W4226127130 cites W2604639891 @default.
• W4226127130 cites W2726463501 @default.
• W4226127130 cites W2743231964 @default.
• W4226127130 cites W2744750020 @default.
• W4226127130 cites W2766071257 @default.
• W4226127130 cites W2789249584 @default.
• W4226127130 cites W2797780288 @default.
• W4226127130 cites W2806116757 @default.
• W4226127130 cites W2809512087 @default.
• W4226127130 cites W2890381929 @default.
• W4226127130 cites W2892354513 @default.
• W4226127130 cites W2908888534 @default.
• W4226127130 cites W2916052887 @default.
• W4226127130 cites W2936890487 @default.
• W4226127130 cites W2965614889 @default.
• W4226127130 cites W2966453812 @default.
• W4226127130 cites W2967846672 @default.
• W4226127130 cites W2975426938 @default.
• W4226127130 cites W2979808837 @default.
• W4226127130 cites W3010013680 @default.
• W4226127130 cites W3010353587 @default.
• W4226127130 cites W3012208565 @default.
• W4226127130 cites W3013320481 @default.
• W4226127130 cites W3014358526 @default.
• W4226127130 cites W3040612311 @default.
• W4226127130 cites W3084424983 @default.
• W4226127130 cites W3086650356 @default.
• W4226127130 cites W3126788809 @default.
• W4226127130 cites W3127970598 @default.
• W4226127130 cites W3185172283 @default.
• W4226127130 doi "https://doi.org/10.3171/2021.10.jns211410" @default.
• W4226127130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35171833" @default.
• W4226127130 hasPublicationYear "2022" @default.
• W4226127130 type Work @default.
• W4226127130 citedByCount "3" @default.
• W4226127130 countsByYear W42261271302022 @default.
• W4226127130 countsByYear W42261271302023 @default.
• W4226127130 crossrefType "journal-article" @default.
• W4226127130 hasAuthorship W4226127130A5017468691 @default.
• W4226127130 hasAuthorship W4226127130A5030704684 @default.
• W4226127130 hasAuthorship W4226127130A5043879863 @default.
• W4226127130 hasAuthorship W4226127130A5052966036 @default.
• W4226127130 hasAuthorship W4226127130A5054814683 @default.
• W4226127130 hasAuthorship W4226127130A5056072781 @default.
• W4226127130 hasAuthorship W4226127130A5058373918 @default.
• W4226127130 hasAuthorship W4226127130A5059739662 @default.
• W4226127130 hasAuthorship W4226127130A5059890725 @default.
• W4226127130 hasAuthorship W4226127130A5060868189 @default.
• W4226127130 hasAuthorship W4226127130A5066158171 @default.
• W4226127130 hasAuthorship W4226127130A5068359755 @default.
• W4226127130 hasAuthorship W4226127130A5080962078 @default.
• W4226127130 hasAuthorship W4226127130A5084998801 @default.
• W4226127130 hasAuthorship W4226127130A5090675288 @default.
• W4226127130 hasConcept C121608353 @default.
• W4226127130 hasConcept C126322002 @default.
• W4226127130 hasConcept C126838900 @default.
• W4226127130 hasConcept C141071460 @default.
• W4226127130 hasConcept C143998085 @default.
• W4226127130 hasConcept C2778164965 @default.
• W4226127130 hasConcept C2778822529 @default.

• next